WO2005080323A1 - Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide - Google Patents
Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide Download PDFInfo
- Publication number
- WO2005080323A1 WO2005080323A1 PCT/IN2005/000055 IN2005000055W WO2005080323A1 WO 2005080323 A1 WO2005080323 A1 WO 2005080323A1 IN 2005000055 W IN2005000055 W IN 2005000055W WO 2005080323 A1 WO2005080323 A1 WO 2005080323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aminopropyl
- methoxybenzenesulfonamide
- hours
- methanol
- diastereomeric salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to an improved and simplified process for the preparation of enantiomerically pure R-(-) or S-(+)-5-(2- aminopropyl)-2- methoxybenzenesulfonamide by resolution of (R,S)-5-(2-aminopropyl)-2- methoxybenzenesulfonamide with D-(-) or L-(+)-tartaric acid, respectively, which is described in Indian Patent Application No.: 1153/MUM/2002; PCT Patent Application No.: PCT/TN02/00244;filed on 26 th December 2002, filed by Cadila Healthcare Ltd.
- the present invention relates to an improved process for the manufacturing of a highly optically pure (R)-(-)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide (Chiral purity: >99.9%) of Formula I, which is a key intermediate for the preparation of Tamsulosin having Formula II (EP-34432, US-4703063) useful in the treatment of patients with symptomatic Benign Prostatic Hyperplasia (BPH).
- Tamsulosin is a selective blocker of otic -receptors, which shows a selective effect during treatment of problems related to hyperplasic prostate without influencing blood pressure or heart action (Honda K. and Nakagawa C: ⁇ radrenoceptor antagonist effect of optical isomer YM-12617 in rabbit lower urinary tract and prostate- J. Pharma. Exp. Ther. 239,512 (1986)).
- the group of compounds as described in patent EP 34 432 have characteristic for their ability to block -adrenergic receptors, which led to their use in treating a number of diseases, especially hypertension, congestive heart failure or problems related to the urinary tract.
- the present invention provides a simplified process for the manufacture of optically pure R-(-) or S-(+)-5-(2-aminopropyl)-2-methoxy benzene sulfonamide (I), which comprises the resolution of (R,S)-5-(2-amino propyl)-2- methoxybenzenesulfonamide with D-(-) or L-(+)-tartaric to form a mixture of diastereomeric salts, separating the diastereomeric salts in a mixture of solvent systems of the kind such as described herein at a specified temperature range.
- the diastereomeric salt thus obtained is kinetically resolved two times in a same solvent system and under similar operational conditions to get desired optical purity (> 99.9%).
- the purified diastereomeric salt is then basified to generate free (R)-(-)-5-(2-amino- propyl)-2-methoxybenzenesulfonamide (I) (Scheme - 1).
- (R,S)-5-(2- aminopropyl)-2-methoxybenzenesulfonamide can be prepared by the process as disclosed in our previous patent i.e., PCT International Application No.: PCT/IN02/00244 filed on 26 th December 2002.
- the molar ratio of (R, S)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide to the D-(-)-tartaric acid is 1:1 to 1:1.5, preferably, 1: 1.1.
- the diastereomeric salt formation as well as resolution is preferably carried out in a same solvent or the mixture of solvent system. It has been observed that the resolution of (R,S)-5-(2-aminopropyl)-2- methoxybenzenesulfonamide with D-(-)-tartaric acid is largely governed by the polarity of the solvent system used.
- the solvent system preferred is a combination of alcoholic solvents such as methanol, ethanol, 1-propanol and 2-propanol with 0-80%(v/v) of dipolar solvents such as N,N-dimethylformamide, N,N,-dimethylacetamide, N-methyl- 2-pyrrolidone; dimethylsulfoxide or water.
- alcoholic solvents such as methanol, ethanol, 1-propanol and 2-propanol
- dipolar solvents such as N,N-dimethylformamide, N,N,-dimethylacetamide, N-methyl- 2-pyrrolidone; dimethylsulfoxide or water.
- water alone can also be used for salt formation as well as resolution at ambient temperature, however in order to obtain optimum yield and optical purity, it is also used in combination with alcoholic solvents.
- the temperature also plays a key role in kinetic resolution for obtaining the optically pure (R)-(-)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide. It has been also observed that if the resolution is carried out at 10-75°C temperature, the desired product is obtained in a higher optical purity. Thus the temperature between 30-65°C range provides the best results.
- the reaction time may also vary between 0 to 26 hours after the addition of the amine to the tartaric acid; however under optimal reaction conditions, the preferred reaction time is 4-8 hours to obtain the optimum yield with desired optical purity.
- the separated diastereomeric salt (R:2S,3S) from the reaction mass is isolated by filtration.
- Moderately resolved diastereomeric salt may also be further purified twice using same solvent system, under similar operational conditions, the purified salt is then treated with a base, i.e. alkali hydroxides, carbonates and hydrogen carbonates, preferably sodium hydroxide to bring pH 9.5-10.0 to obtain (R)-(-)-5-(2-aminopropyl)- 2-methoxybenzenesulfonamide as free base.
- a base i.e. alkali hydroxides, carbonates and hydrogen carbonates, preferably sodium hydroxide to bring pH 9.5-10.0 to obtain (R)-(-)-5-(2-aminopropyl)- 2-methoxybenzenesulfonamide as free base.
- the mother liquor obtained from I and II crystallization contains 70-85% R- isomer of 5-(2-aminopropyl)-2-methoxybenzenesulfonamide as tartarate salt, that can be mixed in another batch during I purification to enhance the productivity.
- the resolving agent D-(-)-tartaric acid can be recovered from the aqueous mother liquor by usual known methods, as reported in literature and reused for the same resolution. Besides D-(-)-tartaric acid, L-(+)-tartaric acid may also be used as a resolving agent.
- the resolution of (R,S)-5-(2-aminopropyl)-2-methoxybenzenesulfonamde using L-(+)-tartaric acid is also carried out in the same fashion. However in this case,
- (S:2R,3R) diastereomeric salt separates out from the reaction mixture which after desalting gives the S-(+)-5-(2-aminopropyl)-2-methoxy benzene sulfonamide.
- (R,S)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide is treated with 1.1 molar ratio of D-(-)-tartaric acid in 8.5 volumes of methanol and 1.7 volumes of dimethylformamide at 60-65°C for 6 hours. The obtained solid is filtered at 60-65°C. The cake is slurrified with 3.0 volume of methanol, filtered and washed with 0.25 volumes of methanol.
- the wet product thus obtained is dried at 50-55°C till constant weight to give 70-75% yield of diastereomeric salt containing R- isomer 84-87% and S-isomer 13-16% as determined on chiral HPLC.
- the obtained salt is refluxed in 6.5 volumes of aqueous methanol containing 38.5% (v/v) water for 1 hour, then cooled to 40-45°C and maintained the same temperature for another 2 hours.
- the resulting mass is further cooled to 30-35°C and aged for 6 hours at same temperature range.
- the obtained solid is filtered and washed twice with 0.25 volumes of methanol as that of tartarate salt.
- the salt is dried at 50- 55°C till constant weight to give 65-70% yield of purified diastereomeric salt containing R-isomer 98-99% and S-isomer 1-2% as determined on chiral HPLC.
- the above obtained purified salt is again refluxed in 6.5 volumes of aqueous methanol containing 38.5% (v/v) water for 1 hour, then cooled to 40-45°C and maintained this temperature for 2 hours.
- the resulting mass is further cooled to 30- 35°C and aged for 6 hours at same temperature range.
- the solid is filtered and then washed twice with 0.25 volumes of methanol as that of the tartarate salt.
- the salt is dried at 50-55°C till constant weight to give 65-70% yield of diastereomeric salt containing R-isomer 99.90-99.95% and S-isomer 0.05-0.10% as determined on chiral HPLC.
- the present invention describes a simple methodology to get first moderately resolved tartarate salt of (R,S)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide, which on subsequent two simple purification with same solvent system provides a diastereomeric salt with high optical purity i.e., more than 99.9%.
- the present invention provides a highly optical pure (>99.9%) 5-(2- aminopropyl)-2-methoxybenzenesulfonamide with overall yield of 33-35% (without recyclable crop) from racemic 5-(2-aminopropyl)-2-methoxybenzene sulfonamide.
- the present method is also capable of reducing S-isomer from 50% to less than 0.05% thereby increasing the optical purity of R-(-)-5-(2-aminopropyl)-2- methoxybenzenesulfonamide from 50.0% to 99.95% exhibiting a successful kinetic resolution of diastereoisomeric salt.
- the present invention is further described in greater detail as illustrated in the following of examples.
- Example: 4 [A] A mixture of 100 g of R-(-)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide tartarate (obtained in Example-2), 400 ml methanol and 250 ml water was refluxed for 1 hour. The clear solution was slowly cooled to 40-45°C and maintained for 2 hours at 40-45°C. The reaction mass further cooled to 28-30°C and stirred for 6 hours at same temperature.
- reaction mass further cooled to 28-30°C and. stirred for 6 hours at same temperature.
- Example: 5 Purification of R-(-)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide tartarate [A] A mixture of 56.0 g of R-(-)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide tartarate (obtained in Example-4A), 224 ml methanol and 140 ml water was refluxed for 1 hour. The clear solution was slowly cooled to 40-45 °C and maintained at 40-45°C for 2 hours. The reaction mass further cooled to 28-30°C and stirred for 6 hours at same temperature.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05747340A EP1720830A1 (en) | 2004-02-23 | 2005-02-22 | Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide |
CA002560347A CA2560347A1 (en) | 2004-02-23 | 2005-02-22 | Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide |
US10/589,999 US20080033208A1 (en) | 2004-02-23 | 2005-02-22 | Process for Manufacturing Optically Pure (R) or (S)-5-(2-Aminopropyl)-2-Methoxybenzene Sulfonamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN218/MUM/2004 | 2004-02-23 | ||
IN218MU2004 | 2004-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005080323A1 true WO2005080323A1 (en) | 2005-09-01 |
Family
ID=34878800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000055 WO2005080323A1 (en) | 2004-02-23 | 2005-02-22 | Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080033208A1 (en) |
EP (1) | EP1720830A1 (en) |
CA (1) | CA2560347A1 (en) |
WO (1) | WO2005080323A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012101648A1 (en) * | 2011-01-24 | 2012-08-02 | Havaldar Freddy H | Novel process for the synthesis of enantiomerically pure 2-methoxy-5-[(2r)-2-(4-alkylpiperazin-l-yl)propyl]-benzenesulfonamide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0257787A1 (en) * | 1986-07-21 | 1988-03-02 | Yamanouchi Pharmaceutical Co. Ltd. | Process for producing optically active benzene-sulfonamide derivates |
CA1282077C (en) * | 1985-11-13 | 1991-03-26 | Kunihiro Niigata | Process for producing substituted-phenethylamine derivatives |
-
2005
- 2005-02-22 WO PCT/IN2005/000055 patent/WO2005080323A1/en active Application Filing
- 2005-02-22 CA CA002560347A patent/CA2560347A1/en not_active Abandoned
- 2005-02-22 EP EP05747340A patent/EP1720830A1/en not_active Withdrawn
- 2005-02-22 US US10/589,999 patent/US20080033208A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282077C (en) * | 1985-11-13 | 1991-03-26 | Kunihiro Niigata | Process for producing substituted-phenethylamine derivatives |
EP0257787A1 (en) * | 1986-07-21 | 1988-03-02 | Yamanouchi Pharmaceutical Co. Ltd. | Process for producing optically active benzene-sulfonamide derivates |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012101648A1 (en) * | 2011-01-24 | 2012-08-02 | Havaldar Freddy H | Novel process for the synthesis of enantiomerically pure 2-methoxy-5-[(2r)-2-(4-alkylpiperazin-l-yl)propyl]-benzenesulfonamide |
Also Published As
Publication number | Publication date |
---|---|
EP1720830A1 (en) | 2006-11-15 |
CA2560347A1 (en) | 2005-09-01 |
US20080033208A1 (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002330774B9 (en) | Process for resolution of tamsulosin | |
WO2011124704A1 (en) | Process for preparing an intermediate for silodosin | |
AU2002330774A1 (en) | Process for resolution of tamsulosin | |
AU2002330776A1 (en) | Racemic tamsulosin free base and methods of making the same | |
JP5097770B2 (en) | Method for preparing Dorzolamide | |
CA2719778A1 (en) | Method for preparing argatroban monohydrate | |
JP2010510253A (en) | Novel process for the preparation of 4,4 '-(1-methyl-1,2-ethanediyl) -bis- (2,6-piperazinedione) | |
JP4932728B2 (en) | Process for producing enantiomers of amlodipine with high optical purity | |
EP1720830A1 (en) | Process for manufacturing optically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzene sulfonamide | |
EP1828110B1 (en) | Process for the preparation of tamsulosin and intermediates thereof | |
KR20110086723A (en) | How to Optically Split a Zopiclone | |
KR100868160B1 (en) | Method for preparing S-(-)-amlodipine or salts thereof and intermediates used therein | |
EP1765828B1 (en) | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | |
EP1603866B1 (en) | A process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | |
WO2007031823A1 (en) | An improved process for preparing tamsulosin hydrochloride | |
EP1905758A1 (en) | Tamsulosin free base and recovery process thereof | |
WO2011004778A1 (en) | Method for producing optically active compound | |
KR20100022272A (en) | A novel method for preparing s-(-)-amlodipine from racemic amlodipine | |
MXPA06008441A (en) | Process for preparation of 1-(2s, 3s)-2-benzhydryl-n -(5-tert-butyl-2 -methoxybenzyl) quinuclidin-3 -amine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005747340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2560347 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005747340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10589999 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10589999 Country of ref document: US |